The company focuses its efforts on the therapeutic areas of oncology, neurology, inflammation/immunology, cardiovascular and infectious diseases.

In September 2017, it was announced that Simcere had signed a deal with US biotech major Amgen for the development of biosimilars for the Chinese market.